73 Healthcare momentum stocks rated Buy or better (Nov 2026)
73 Healthcare momentum stocks rated Buy or better by the Lician Quant rating as of Nov 4, 2026, including Exelixis Inc (EXEL), Revvity Inc. (RVTY), Charles River Laboratories (CRL). Momentum grade A- or better (1, 3, 6 and 12-month price performance against sector peers) and a Buy or Strong Buy rating.
Open this screen in the full screener to add filters, sort by any factor and save it.
73 stocks · Strong Buy or Buy · Healthcare · Momentum ≥ A-
| Stock | Quant ratingRating | ValuationVal | GrowthGrow | ProfitabilityProf | MomentumMom | EPS revisionsRev | Market capMkt cap | P/EP/E | Revenue growthRev YoY | Div. yieldYield | Short % floatShort | Next earningsEarnings |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1CDNACareDx Inc | 4.98Strong Buy | C+ | B+ | A+ | A+ | A+ | $3.6B | 32.2 | +34.4% | — | 13.6% | — |
| 2HNGEHinge Health, Inc. | 4.56Strong Buy | B+ | — | A+ | A+ | F | $1.9B | 17.3 | — | — | — | — |
| 3AMNAMN Healthcare Services Inc | 4.83Strong Buy | A+ | D+ | B- | A+ | A- | $1.6B | 14.9 | +24.0% | — | 10.0% | Nov 5 |
| 4HAEHaemonetics Corporation | 4.70Strong Buy | B+ | C- | B+ | A+ | B+ | $5.4B | 56.1 | +0.4% | — | 7.6% | Nov 5 |
| 5CRLCharles River Laboratories | 3.79Buy | C+ | F | B- | A+ | B | $16.9B | NM | -0.7% | — | 5.8% | Nov 4 |
| 6HALOHalozyme Therapeutics Inc | 4.97Strong Buy | C | B+ | A+ | A+ | A+ | $14.7B | 35.4 | +41.2% | — | 11.2% | Nov 5 |
| 7KNSAKiniksa Pharmaceuticals Ltd | 4.89Strong Buy | B- | A+ | A | A+ | C | $4.1B | 37.7 | +58.2% | — | 9.6% | — |
| 8KIDSOrthopediatrics Corp | 4.02Buy | B- | B+ | C+ | A+ | F | $793M | NM | +16.1% | — | 5.7% | — |
| 9LFSTLifestance Health Group Inc | 4.52Strong Buy | B+ | B+ | B+ | A+ | D | $5.1B | 101.0 | +20.4% | — | — | Nov 5 |
| 10SGHTSight Sciences Inc | 3.84Buy | D | D+ | C | A+ | A | $494M | NM | +9.3% | — | — | Nov 4 |
| 11SEPNSepterna, Inc. Common Stock | 4.17Buy | D- | B | C+ | A+ | A+ | $1.9B | NM | +13,520% | — | — | Nov 9 |
| 12ATRCAtriCure Inc | 4.12Buy | C+ | B | B | A+ | D | $3.0B | 284.2 | +13.9% | — | 10.1% | — |
| 13EXELExelixis Inc | 4.69Strong Buy | C+ | B | A+ | A+ | C- | $17.5B | 19.7 | +9.1% | — | 13.4% | — |
| 14CONConcentra Group Holdings Parent, Inc. | 4.94Strong Buy | A- | B- | A- | A+ | B | $5.0B | 25.4 | +14.0% | 0.99% | 3.1% | Nov 5 |
| 15HTFLHeartflow, Inc. Common Stock | 3.66Buy | F | — | C | A+ | B+ | $4.5B | NM | — | — | — | Nov 12 |
| 16RVTYRevvity Inc. | 4.47Buy | B+ | D- | B+ | A+ | B+ | $17.1B | 71.8 | +4.1% | — | 5.5% | — |
| 17TGTXTG Therapeutics Inc | 4.43Buy | C+ | A+ | A | A+ | F | $8.1B | 18.4 | +76.1% | — | — | — |
| 18SIBNSi-Bone Inc | 4.08Buy | C- | B+ | B- | A+ | C | $949M | NM | +15.3% | — | — | — |
| 19NRCNational Research Corp | 4.42Buy | B- | C | A- | A+ | C+ | $452M | 77.2 | -0.2% | 3.03% | — | — |
| 20LLYEli Lilly and Company | 4.65Strong Buy | — | A | A+ | A+ | F | — | — | +45.5% | 0.56% | — | — |
| 21LUNGPulmonx Corp | 4.27Buy | B | C- | D+ | A+ | A+ | $129M | NM | -3.4% | — | 1.8% | — |
| 22PBYIPuma Biotechnology Inc | 3.82Buy | A | D- | A- | A+ | F | $534M | 20.0 | -2.9% | — | 11.9% | Nov 5 |
| 23PCRXPacira BioSciences, Inc. | 4.67Strong Buy | A | D | B+ | A | B+ | $1.4B | 98.9 | +5.7% | — | — | Nov 5 |
| 24AVAHAveanna Healthcare Holdings Inc | 4.99Strong Buy | A | A- | B+ | A | A+ | $2.9B | 10.6 | +19.5% | — | 10.2% | Nov 12 |
| 25BTSGBrightSpring Health Services, Inc. Common Stock | 4.96Strong Buy | A- | A- | B- | A | — | $11.6B | 28.4 | +22.9% | — | 12.0% | — |
Showing 25 of 73
Source: Lician Quant Grades (SEC EDGAR statements, EODHD prices and estimates); short interest: FINRA; earnings dates: earnings calendar; dividend yield: EODHD fundamentals · Quant run Nov 4, 2026
Grades rank each stock against its sector peers; they are not investment advice. How the rating and grades work · Short interest · Earnings calendar
Momentum leaders in other sectors
About this screen
- Which are the top Healthcare momentum stocks rated Buy or better?
- As of Nov 4, 2026, the highest ranked are CareDx Inc (CDNA, rating 4.98); Hinge Health, Inc. (HNGE, rating 4.56); AMN Healthcare Services Inc (AMN, rating 4.83); Haemonetics Corporation (HAE, rating 4.70); Charles River Laboratories (CRL, rating 3.79). 73 stocks pass the screen in total.
- What does this screen look for?
- Momentum grade A- or better (1, 3, 6 and 12-month price performance against sector peers) and a Buy or Strong Buy rating.
- How is the Lician Quant rating calculated?
- Each stock gets five factor grades (Valuation, Growth, Profitability, Momentum, EPS Revisions) from A+ to F by ranking its metrics against the other stocks in its sector. The rating (1.00 to 5.00) is the equal-weight average of the factor scores, re-ranked within the sector: 4.50 and up is Strong Buy, 3.50 Buy, 2.50 Hold, 1.50 Sell, below that Strong Sell.
- How often is the list updated?
- After every US trading day, from SEC filings, EODHD prices and analyst estimates; this list is from the quant run of Nov 4, 2026. Short interest follows FINRA's twice-monthly settlement dates.